Argeron NephroTest is an in vitro diagnostic test designed for renal function assessment and kidney disease screening. The test facilitates early detection of nephropathy through reliable biomarker analysis, supporting clinical decision-making in nephrology and primary care settings.
Manufactured by
ARGERON MEDİKAL ARAŞ.SAN.VE TİC.A.Ş.
Türkiye
Argeron Medical is an innovative company specializing in the development of healthcare technologies for aging and biological age determination. We work particularly with in vitro diagnostic kits and biomarker-based tests to enable early diagnosis of age-related diseases. We offer solutions for understanding biological aging processes, as well as cancer, kidney damage, Alzheimer's, and other neurodegenerative diseases. Our products, which hold CE quality certificates, are manufactured in accordance with IVDR quality standards. Our company successfully manages national and international patent portfolios.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
Bio Preventive Medicine Co. Ltd.
Taiwan · 4 relevant products
BioPorto Diagnostics
United States · 5 relevant products
Hipro Biotechnology Co., Ltd. CE CIBG
China · 1 relevant product
62 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →7 more sourcing countries available
Get free access to all sourcing countries identified for this product.
See all countries →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
3 of 92 closest product alternatives
Bio Preventive Medicine Co. Ltd. · Taiwan
A non-invasive urine-based diagnostic test designed to predict rapid kidney function deterioration in chronic kidney disease patients. This biomarker assay provides quantitative risk assessment to support early clinical intervention and disease management.
BioPorto Diagnostics · United States
CE-marked in vitro diagnostic test for early detection of acute kidney injury using the NGAL biomarker. Identifies kidney damage earlier than traditional serum creatinine and urine output methods, enabling timely clinical intervention.
BioPorto Diagnostics · United States
FDA-cleared biomarker test for pediatric acute kidney injury risk assessment. Available for use on Roche Diagnostics Cobas c 501 clinical chemistry analyzer to rapidly identify kidney damage in pediatric patients.
89 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products